Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

'Incorrect' To Assume Interchangeables Are Safer, More Effective Than Biosimilars, Says FDA

Executive Summary

US FDA India country director Dr Sarah McMullen provides a fact check at a recent conclave to dispel the notion that interchangeable biosimilars are safer and more effective than other approved biosimilars.

You may also be interested in...



Revlimid Generic Revs Up Dr Reddy’s To Record Gains, There’s More To Come

Generic Revlimid US sales propel Dr Reddy’s to a record fiscal second quarter, with the management indicating that “meaningful” contributions are likely in the coming months too. The Indian firm also expects to deploy its healthy cash flows for deal-making, aided by tempered valuations in some segments amid geopolitical and economic turbulence.

Revlimid Generic Revs Up Dr Reddy’s To Record Gains, There’s More To Come

Generic Revlimid US sales propel Dr Reddy’s to a record fiscal second quarter, with the management indicating that “meaningful” contributions are likely in the coming months too. The Indian firm also expects to deploy its healthy cash flows for deal-making, aided by tempered valuations in some segments amid geopolitical and economic turbulence.

FDA To Pilot Biosimilar Regulatory Science Program

As part of BsUFA III, the FDA has announced that it will be commencing its regulatory science research program, which will focus on advancing the development of interchangeable products and biosimilars.

Related Content

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

PS147050

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel